Latest News

ADAPs achieve 87% viral suppression but face funding crisis as multiple policies erode 340B rebates.

340B program drifted from patient benefit; federal reform needed for transparency and accountability.

Senate HELP Committee hearing reveals how 340B drug program expansion reflects hospital business strategy rather than patient benefit.

Congressional Budget Office confirms 340B program expansion driven by hospital exploitation rather than pharmaceutical price inflation.

HRSA clarifies 340B eligibility for STI clinics while manufacturers challenge Ryan White program participation.

HRSA's 340B pilot program replicates existing successful models rather than addressing structural program exploitation.

340B program expansion drains billions from state Medicaid budgets while failing to deliver promised drug cost savings.

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

Pugh reflects on 340B policy and patient advocacy in ensuring equitable medication access.

2024 federal healthcare policy priorities: 340B reform, PBM oversight, and telehealth.

PDABs and upper-payment limits risk restricting medication access despite affordability intentions.

$100 billion 340B program lacks patient accountability; reform needed for charitable care obligations.

CMS's $9B remedy to hospitals after SCOTUS 340B ruling lacks enforcement of charitable care requirements.

340B reform must prioritize patients: charity care obligations and medical debt reduction.

Nashville Fireside Chat: state funding cuts, 340B reform, and HIV criminalization law changes.

Hospital price transparency and 340B lack accountability while patients face medical debt.

ADAP Fireside Chat addresses counterfeit medications, 340B reform, and public health workforce sustainability.

S.4395 would divert Ryan White resources from PLWHA to PrEP, threatening the safety net for vulnerable populations.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.